visilizumab

A substance being studied in the treatment of an immune system reaction called graft-versus-host disease (GVHD), which may occur after a donor stem cell transplant. It is also being studied in the treatment of some autoimmune diseases. Visilizumab binds to a protein called CD3, which is found on some T cells (a type of white blood cell). This may help suppress the body’s immune response. Visilizumab is a type of monoclonal antibody.